Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung.

PURPOSE We used normal tissue complication probability (NTCP) modeling to explore the impact of heart irradiation on radiation-induced lung fibrosis (RILF). MATERIALS AND METHODS We retrospectively reviewed for RILF 148 consecutive Hodgkin lymphoma (HL) patients treated with sequential chemo-radiotherapy (CHT-RT). Left, right, total lung and heart dose-volume and dose-mass parameters along with clinical, disease and treatment-related characteristics were analyzed. NTCP modeling by multivariate logistic regression analysis using bootstrapping was performed. Models were evaluated by Spearman Rs coefficient and ROC area. RESULTS At a median time of 13months, 18 out of 115 analyzable patients (15.6%) developed RILF after treatment. A three-variable predictive model resulted to be optimal for RILF. The two models most frequently selected by bootstrap included increasing age and mass of heart receiving >30Gy as common predictors, in combination with left lung V5 (Rs=0.35, AUC=0.78), or alternatively, the lungs near maximum dose D2% (Rs=0.38, AUC=0.80). CONCLUSION CHT-RT may cause lung injury in a small, but significant fraction of HL patients. Our results suggest that aging along with both heart and lung irradiation plays a fundamental role in the risk of developing RILF.

[1]  J. Yarnold,et al.  Pathogenetic mechanisms in radiation fibrosis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Christine F. Wogan,et al.  Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. , 2015, International journal of radiation oncology, biology, physics.

[3]  R. D. de Boer,et al.  Physiological interaction of heart and lung in thoracic irradiation. , 2012, International journal of radiation oncology, biology, physics.

[4]  R. Tsang,et al.  Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. , 2005, International journal of radiation oncology, biology, physics.

[5]  Benjamin Movsas,et al.  Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. , 2011, International journal of radiation oncology, biology, physics.

[6]  Joos V Lebesque,et al.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[7]  Joseph O. Deasy,et al.  Complication Probability Models for Radiation-Induced Heart Valvular Dysfunction: Do Heart-Lung Interactions Play a Role? , 2014, PloS one.

[8]  S. Gerson,et al.  DNA repair defects in stem cell function and aging. , 2005, Annual review of medicine.

[9]  M. Salvatore,et al.  Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques , 2010, Radiation oncology.

[10]  Issam El Naqa,et al.  Heart irradiation as a risk factor for radiation pneumonitis , 2011, Acta oncologica.

[11]  Andrew Jackson,et al.  The atlas of complication incidence: a proposal for a new standard for reporting the results of radiotherapy protocols. , 2006, Seminars in radiation oncology.

[12]  E. Hatzimichael,et al.  Revisiting bleomycin from pathophysiology to safe clinical use. , 2013, Critical reviews in oncology/hematology.

[13]  Gulshan Sharma,et al.  Effect of aging on respiratory system physiology and immunology , 2006, Clinical interventions in aging.

[14]  J. Dang,et al.  Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy , 2013, Acta oncologica.

[15]  R. D. de Boer,et al.  ACE inhibition attenuates radiation-induced cardiopulmonary damage. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Jeffrey D Bradley,et al.  Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk. , 2015, Medical physics.

[17]  M. Martel,et al.  Radiation dose-volume effects in the lung. , 2010, International journal of radiation oncology, biology, physics.

[18]  I El Naqa,et al.  Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose–volume outcome relationships , 2006, Physics in medicine and biology.

[19]  M. Anscher,et al.  Radiation pulmonary toxicity: from mechanisms to management. , 2010, Seminars in radiation oncology.

[20]  J. Deasy,et al.  Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. , 2006, International journal of radiation oncology, biology, physics.

[21]  Debra H Brinkmann,et al.  Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. , 2007, International journal of radiation oncology, biology, physics.

[22]  Aamer Chughtai,et al.  Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. , 2011, International journal of radiation oncology, biology, physics.

[23]  C. Mandarim-de-Lacerda,et al.  Up-regulation of angiotensin-converting enzyme and angiotensin II type 1 receptor in irradiated rats , 2010, International journal of radiation biology.

[24]  M. Salvatore,et al.  Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury , 2014, Acta oncologica.

[25]  A. Olch,et al.  Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation , 2014, Pediatric blood & cancer.

[26]  I. Vogelius,et al.  A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis , 2012, Acta oncologica.

[27]  C. Rübe,et al.  Accumulation of DNA Damage in Hematopoietic Stem and Progenitor Cells during Human Aging , 2011, PloS one.

[28]  Johannes A Langendijk,et al.  The impact of heart irradiation on dose-volume effects in the rat lung. , 2007, International journal of radiation oncology, biology, physics.

[29]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[30]  A. LaCasce,et al.  Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. , 2012, International journal of radiation oncology, biology, physics.

[31]  Georgi Nalbantov,et al.  Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  M. C. Pressello,et al.  Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms , 2013, Radiation Oncology.

[33]  R. Mohan,et al.  Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort , 2014, Acta oncologica.

[34]  Lawrence B. Marks,et al.  ALERT - Adverse Late Effects of Cancer Treatment , 2014 .

[35]  J. Deasy,et al.  Predicting radiation-induced valvular heart damage , 2015, Acta oncologica.

[36]  Joseph O Deasy,et al.  CERR: a computational environment for radiotherapy research. , 2003, Medical physics.